![PTAB invalidates three patents covering Teva's Copaxone, opens door for Mylan's generic version - IPWatchdog.com | Patents & Intellectual Property Law PTAB invalidates three patents covering Teva's Copaxone, opens door for Mylan's generic version - IPWatchdog.com | Patents & Intellectual Property Law](https://ipwatchdog.com/wp-content/uploads/2016/09/Copaxone.jpg)
PTAB invalidates three patents covering Teva's Copaxone, opens door for Mylan's generic version - IPWatchdog.com | Patents & Intellectual Property Law
![Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1601469710/Copaxone.jpg/Copaxone.jpg?VersionId=PhbA.kpjNFb3A_uch5krsTbbBmdM_mNL)
Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma
![Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity](https://mma.prnewswire.com/media/567358/Mylan_BHBW.jpg)